Trial reportNeurology(R) neuroimmunology & neuroinflammation2026
Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis.
Trial report in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00288626 (A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
BACKGROUND AND
objectivesAutologous hematopoietic stem cell transplantation (AHSCT) can induce long-lasting immune tolerance and disease quiescence in patients with severe multiple sclerosis (MS), but the underlying mechanisms are not well understood. We hypothesized that AHSCT would induce persistent decreases in inflammatory cytokines, chemokines, and axoglial damage biomarkers in serum and CSF.
methodsLongitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48. Approximately 50 soluble biomarkers were analyzed to determine treatment-induced changes and associations with disease activity, including clinical and MRI parameters.
resultsAHSCT resulted in decreased expression of many proinflammatory cytokines, chemokines, and neuroinflammatory markers for several years in both serum and CSF, including neurofilament light chain (NfL). CSF levels of glial fibrillary acid protein and IL-7, on the contrary, increased after treatment. Expansion of cytomegalovirus and/or Epstein-Barr virus early after AHSCT resulted in transient increases in inflammatory cytokines in serum, but these changes did not persist. Changes in serum were largely distinct from changes in CSF, and concentrations of cytokines and chemokines in serum rarely correlated with concentrations in CSF, except for NfL. DISCUSSION: These results confirm the hypothesis that AHSCT results in long-lasting reductions in inflammatory cytokines, chemokines, and axoglial damage markers, consistent with persistent disease quiescence. The lack of relationships between biomarkers in serum and CSF suggests that these samples largely reflect distinct immunologic processes and compartments, and that analysis of CSF may be warranted for deeper understanding of disease processes in the CNS despite the challenges associated with performing lumbar punctures. Expression of IL-7 in CSF may be an underappreciated biomarker of the inflammatory state in the CNS and warrants further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.